CLINICAL_TRIALS trial_result · 2025-02-21

Clinical Trial Update: A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease [Phase 3]

Phase 3 study evaluating subcutaneous guselkumab for moderately to severely active Crohn's disease; results have been posted for this trial update.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Janssen Research & Development, LLC | Conditions: Crohn Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-02-21